In CMS
Jul 13th, 2012
A request from the Medical Imaging & Technology Alliance (MITA) and other stakeholders has the Centers for Medicare & Medicaid Services (CMS) reconsidering coverage of certain uses of positron emission tomography (PET). Section 220.6 of the National Coverage Determination Manual identifies fluorodeoxyglucose F-18, rubidium Rb-82, ammonia N-13, and sodium fluoride F-18 as the only nationally...
In CMS
Apr 29th, 2011
The Centers for Medicare & Medicaid Services (CMS) announced April 25 in a proposed decision memo that there is sufficient evidence to conclude that magnetic resonance imaging (MRI) improves health outcomes for Medicare beneficiaries with implanted permanent pacemakers (PMs). CMS is proposing to change the language in section 220.2.C.1 of the NCD Manual to remove ...
In Coding
Jan 14th, 2011
With the exception of clinical trials, home use of oxygen to treat cluster headaches remains a non-covered Medicare benefit. The Centers for Medicare & Medicaid Services (CMS) released a decision memorandum Jan. 4 stating that there remains insufficient evidence that in-home use of oxygen for the treatment of cluster headaches improves health outcomes. CMS: O2 ...
In Billing
Oct 15th, 2010
Effective for claims with service dates on or after Aug. 4, Medicare will nationally cover the use of allogenic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) when provided in a Medicare-approved clinical study under Coverage Evidence Development (CED). In all other settings, HSCT for MDS is nationally non-covered by Medicare. MDS refers to ...
In CMS
Apr 5th, 2010
The Centers for Medicare & Medicaid Services (CMS) recently revised National Coverage Determination (NCD) 220.6 – Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer. Effective Feb. 26, CMS will cover NaF-18 positron emission tomography (PET) imaging when the Medicare beneficiary’s treating physician determines that it is needed to inform the initial antitumor trea...